Volume 1, Issue 1 (winter 2013)
Clin Exc 2013, 1(1): 1-25 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Babamahmoodi F B M H, Haghshenas M. Treatment of Chronic Hepatitis B Virus Infection. Clin Exc 2013; 1 (1) :1-25
URL: http://ce.mazums.ac.ir/article-1-25-en.html
URL: http://ce.mazums.ac.ir/article-1-25-en.html
MAZUMS
Abstract: (105302 Views)
Hepatitis B virus (HBV) infection is a major global health problem and is a factor for
progressive liver diseases such as chronic hepatitis, cirrhosis and epatocellular carcinoma.
HBV is an envelope, double stranded DNA virus with a genome of approximately 3200 base
pairs.
It has been classified into eight major genotypes (A-H) and multiple subtypes, and HBV
genotypes have distinct geographical distribution of the world. WHO estimation of HBV
prevalence, suggests that there are nearly two billion people worldwide who have been
infected with this virus and more than 350 million of people live with chronic infection (up
to 5% of the world population), of these near one million people die annually from
complications of chronic hepatitis B, which is the 10th leading cause of death worldwide.
Throughout the world, carrier variability rate for hepatitis B infection is estimated to be 0.1%
to 20%, with regions classified as having low (<2%), intermediate (2-7%) and high (>8%)
endemic. In Iran, it is estimated that near 30% of population have been exposed to HBV and
the endemicity is intermediate, with a carrier rate 1.3%-3.8% in the different provinces of
this country. In Iran, the HBV vaccination program has been started in 1993 and after that,
Iran can be considered as one of the countries with low HBV infection endemicity.
The most genotype circulating in some provinces of Iran were genotype D in different
clinical forms of HBV infections. The distribution of HBV genotypes may guide us in
determining disease burden.
It is important to have information about the epidemiology of HBV as response to therapy
and vaccination to control HBV infection. Therefore, its successful treatment has major value
in quality of life of patients infected by HBV. This study designed a systematic review of
chronic HBV infection to determine the successful treatment and following HBV positive
patients.
Subject:
اپيدميولوژي
Received: 2013/01/13 | Accepted: 2013/08/27 | Published: 2013/08/27
Received: 2013/01/13 | Accepted: 2013/08/27 | Published: 2013/08/27
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
